Journal article

Pharmacological and genetic strategies for targeting adenosine to enhance adoptive T cell therapy of cancer

Kevin Sek, Lev M Kats, Phillip K Darcy, Paul A Beavis

Current Opinion in Pharmacology | ELSEVIER SCI LTD | Published : 2020


Adoptive cellular therapy involves the ex vivo expansion of immune cells, conventionally T cells, before reinfusion back to the patient. Variations in adoptive cellular therapy include transduction of a patient's T cells with either a transgenic T cell receptor or chimeric antigen receptor (CAR) to recognize a defined tumor antigen. Given that adenosine is a major axis of immunosuppression of T cells, particularly in hypoxic tumor microenvironments, therapeutics targeting this pathway are currently being assessed for their potential to enhance adoptive T cell therapies. The use of gene-editing technology, commonly used in tandem with CAR and transgenic T cell receptor (TCR) based adoptive ce..

View full abstract